Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cassava Sciences, Inc. - Common Stock (NQ:SAVA)

2.765 -0.175 (-5.95%)
Streaming Delayed Price Updated: 3:43 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
38 39 Next >
News headline image
Cassava Reports Q3 2025 Financials Results and Provides Business Update
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via Business Wire
News headline image
Cassava Sciences Appoints Dawn C. Bir to the Board of Directors
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
Which stocks have an unusual volume on Thursday? ↗
Let's have a look at the stocks with an unusual volume in today's session. 
Via Chartmill
News headline image
Peraso Inc. (NASDAQ: PRSO) Regains Nasdaq Compliance, Earns $2.74 Price Target from Intro-act – More Stocks Inside
Via AB Newswire
News headline image
In today's session, these stocks are experiencing unusual volume. ↗
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
News headline image
Cassava Sciences (SAVA) Soars 18% After CEO's Substantial Investment
Cassava Sciences (NASDAQ: SAVA) witnessed a dramatic surge in its stock price today, climbing an impressive 18% after its President and CEO, Richard Barry, disclosed a significant personal investment... 
Via MarketMinute
Topics Regulatory Compliance
News headline image
Tuesday's session: top gainers and losers ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Keep an eye on the top gainers and losers in Tuesday's session. ↗
Stay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
These stocks are gapping in today's session ↗
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Cassava Sciences (SAVA) Stock Is Surging Tuesday: What's Going On? ↗
Cassava Sciences shares are trading higher Tuesday morning. A Form 4 filing disclosed that CEO Rick Barry acquired 237,941 shares at an average price of $2.25 each. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Super League Enterprise Shares Are Trading Higher By 200%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Curious about the stocks that are showing activity after the closing bell on Monday? ↗
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
Cassava Sciences Posts Q2 Loss on Pivot ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Cassava Reports Q2 2025 Financials Results and Provides Business Update
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
Cassava Reports Q1 2025 Financials Results, Provides Business Update
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
Top movers analysis one hour before the close of the markets on 2025-03-25: top gainers and losers in today's session. ↗
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
Cassava Sciences Stock Drops Over 30% After Alzheimer’s Drug Fails Study – But Retail Remains Hopeful ↗
The drug showed no treatment benefit for patients in the study called REFOCUS-ALZ, the company said, while adding that the Alzheimer’s disease development program with Simufilam will be discontinued by... 
Via Stocktwits
News headline image
Which stocks are experiencing notable movement on Tuesday? ↗
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop ↗
Cassava Sciences is ending simufilam development for Alzheimer's after Phase 3 trials failed. The company is shifting focus to potential seizure treatments. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
38 39 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.